Physician profile
David M Bowman
NPI 1104810829
$721.26
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $76.00 · 2021: $135 · 2022: $172 · 2023: $116 · 2024: $51.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $136.16 | 2019-2024 | Tecnis Iol, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $107.23 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $69.85 | 2020-2022 | |
| Oyster Point Pharma, INC. | $43.23 | 2022 | |
| Bausch & Lomb Americas INC. | $36.73 | 2022-2023 | Vyzulta |
| Harrow Eye, LLC | $33.94 | 2024 | Iheezo, Vevye |
| Carl Zeiss Meditec USA, INC. | $28.50 | 2023 | Artevo 800 |
| Alcon Vision LLC | $26.92 | 2019 | |
| Biotissue Holdings INC. | $26.77 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $25.59 | 2019 | |
| Horizon Therapeutics Plc | $20.64 | 2023 | Tepezza |
| Thea Pharma INC. | $19.81 | 2023 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $17.95 | 2020 | |
| Allergan, INC. | $16.12 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $14.30 | 2020 | |
| Kala Pharmaceuticals, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.